Shows
- Reuters Investigates
- Impact Players
- Politisphere
- Felix TV
- Freeland File
- Tech Tonic
- Moving Pictures
- Fast Forward
- Rough Cuts
- Decoder
- Money Clip
- Investing 201
- Innovations
- Breakingviews
- The Exchange
- Take 120
Topics
Latest Shows
- M
- T
- W
- T
- F
Breakingviews: M&A lacking Elan (3:01)
Feb 25 - Royalty Pharma's $6.6 bln approach for the biotech is at a scrawny 4 percent premium. Richard Beales and Robert Cyran discuss why the specialist investor may still be the right owner – at the right price.

